• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Mcmichael Bryan J covered exercise/tax liability with 1,711 shares, decreasing direct ownership by 7% to 22,951 units (SEC Form 4)

    1/22/25 7:51:11 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    McMichael Bryan J

    (Last) (First) (Middle)
    COHERUS BIOSCIENCES, INC.
    333 TWIN DOLPHIN DRIVE, SUITE 600

    (Street)
    REDWOOD CITY CA 94065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Coherus BioSciences, Inc. [ CHRS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    01/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/20/2025 F 1,711(1) D $1.39 22,951 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.
    /s/ Bryan J. McMichael 01/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHRS

    DatePrice TargetRatingAnalyst
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    11/17/2023$11.00Outperform
    Robert W. Baird
    11/8/2023Buy → Hold
    Maxim Group
    7/24/2023$12.00Buy
    Citigroup
    5/1/2023$24.00Buy
    Truist
    3/28/2023$11.00Neutral → Buy
    UBS
    6/14/2022$7.00Neutral
    UBS
    3/7/2022$15.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

      REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

      5/5/25 4:01:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens Life Science Conference in New York, NY on Thursday, May 8, 2025 at 9:00 a.m. Eastern Daylight Time / 6:00 a.m. Pacific Daylight Time – Webcast LinkHCW BioConnect @ Nasdaq NYC 2025 in New York, NY on Tuesday, May 20, 2025 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time – Webcast LinkTD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA taking place virtually on Tuesday, May 27, 2025 at 3:00 p.m. Eastern Daylight Time / 12:00 p.m. Pacific D

      5/1/25 5:04:28 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

      – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

      4/28/25 10:10:11 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Coherus BioSciences downgraded by UBS with a new price target

      UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously

      8/16/24 7:33:26 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

      Robert W. Baird initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $11.00

      11/17/23 7:37:50 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences downgraded by Maxim Group

      Maxim Group downgraded Coherus BioSciences from Buy to Hold

      11/8/23 9:19:04 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

      5/22/24 9:41:01 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

      4/23/24 4:41:07 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

      12/27/23 4:38:39 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Financials

    Live finance-specific insights

    See more
    • Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

      REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

      5/5/25 4:01:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

      – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

      4/28/25 10:10:11 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

      REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.me

      3/3/25 8:30:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:59:16 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Lanfear Dennis M

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:58:02 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcmichael Bryan J covered exercise/tax liability with 1,711 shares, decreasing direct ownership by 7% to 22,951 units (SEC Form 4)

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      1/22/25 7:51:11 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Coherus BioSciences Inc.

      DEFA14A - Coherus BioSciences, Inc. (0001512762) (Filer)

      4/29/25 4:07:12 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Coherus BioSciences Inc.

      DEF 14A - Coherus BioSciences, Inc. (0001512762) (Filer)

      4/29/25 4:05:21 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Coherus BioSciences, Inc. (0001512762) (Filer)

      4/25/25 4:05:22 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Coherus BioSciences Inc.

      SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)

      11/13/24 4:30:25 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      7/23/24 8:23:56 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      5/22/24 7:27:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

      REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

      6/5/24 9:00:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

       – Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

      7/20/23 4:04:53 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

      - Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to

      5/11/22 6:00:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care